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As life span rises, dementia has become a growing public health issue. According to current estimates, almost 36 
million people are having dementia worldwide, and this num-
ber is expected to reach 66 million by 2030 and 115 million by 
2050.1 In affluent countries, the prevalence of dementia after 
65 years is 5% to 10%.2 Vascular dementia (VaD), the second 
most common cause of dementia after Alzheimer’s disease 
(AD), accounts for at least 20% of cases.3 The prevalence of 
both VaD and AD rises exponentially with age, with the risk 
of VaD doubling every 5.3 years.4,5 There is a decline in inci-
dence rates of dementia in developed countries, which has in 
part been related to improvements in prevention and treatment 
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of vascular diseases.2,6 Yet, the burden of dementia on patients, 
families, health care, and long-term care systems is growing, 
with costs in the United States surpassing those of cancer and 
heart disease.7
The prevalence of vascular cognitive impairment (VCI), 
which includes milder forms of cognitive impairment, is 
strongly age related. In subjects aged 65 to 84 years, the prev-
alence of mild forms of VCI not qualifying for dementia is 
higher than that of VaD.8 Rates of conversion to dementia, in-
stitutionalization, and mortality are significantly increased in 
these patients, identifying patients with VCI as an important 
target population for prevention.3,8–11
Recent studies have highlighted the impact of subtle but 
widespread vascular injury and of ensuing changes in structur-
al and functional connectivity on cognitive function. Also, it is 
now recognized that vascular injury induces secondary tissue 
loss in anatomically connected brain regions.12,13 An improved 
understanding of the contribution of vascular diseases to cog-
nitive decline further originates from studies combining imag-
ing with autopsy or genetics in deeply phenotyped cohorts. 
Many of these data have only recently become available. We 
review current concepts of VCI with an emphasis on mecha-
nisms and on aspects relevant to prevention and treatment.
Defining VCI: Diagnostic Criteria
The concept of VCI evolved from the concept of VaD, which 
marks the end of a continuum of clinical manifestations. There 
have been various efforts to define VaD, including the criteria 
of the International Classification of Disease-Tenth Revision14 
and the Diagnostic and Statistical Manual of Mental disor-
ders (Fourth Edition),15 the National Institute of Neurological 
Disorders and Stroke and the Association Internationale pour 
la Recherche et I’Enseignement en Neurosciences,16 and the 
Alzheimer’s Disease Diagnostic and Treatment Centers.17
These efforts in part reflect changes in the understanding 
and concept of VaD.18 Although earlier work emphasized the 
role of multiple large and small infarcts (multi-infarct demen-
tia),19 it is now recognized that alterations in small blood ves-
sels take center stage in VaD. These alterations are associated 
with more widespread injury throughout the brain20 but most 
prominently involve subcortical structures. As a consequence, 
there have been proposals for separate diagnostic criteria for 
subcortical VaD.21 A detailed discussion of individual classi-
fication systems, including Diagnostic and Statistical Manual 
of Mental disorders (Fifth Edition), is beyond the scope of 
this review. However, available diagnostic criteria vary 
with regard to sensitivity and specificity and are, thus, not 
interchangeable.3,18,22–25
VCI is a broad concept that covers the full spectrum from 
vascular mild cognitive impairment (vascular MCI) to VaD 
and includes cases with mixed pathologies, such as mixed vas-
cular and AD-type pathologies.3,26–28 It refers to all forms of 
cognitive impairment associated with cerebrovascular diseas-
es, regardless of underlying mechanism (eg, multiple or single 
territorial or small infarcts, strategic infarcts) and irrespective 
of the occurrence of stroke symptoms. The key requirements 
for a diagnosis of VCI are (1) demonstration of a cognitive 
deficit by neuropsychological testing and (2) presence of 
cerebrovascular disease. The diagnosis is further classified as 
probable or possible depending on whether there is conclusive 
evidence of a causal relationship between the vascular disease 
and the cognitive syndrome (Table 1).
The pattern of cognitive deficits in VCI is variable, and 
recent criteria for VCI no longer require the presence of mem-
ory impairment, a typical feature of AD.28–30 Hence, neuropsy-
chological testing should cover at least 4 different cognitive 
domains. A diagnosis of VaD requires deficits in at least 2 
domains, whereas deficits in a single domain are sufficient to 
diagnose vascular MCI (Table 1). The latter can be classified 
into 4 subtypes: amnestic, amnestic plus other domains, non-
amnestic single domain, and nonamnestic multiple domains. 
An abnormal test result is usually defined as ≥1 SD below 
the mean of a cognitively healthy control population.31 Some 
definitions of VCI require a subjective report of a cognitive 
decline by the patient or an informant.
Diagnosing vascular disease of the brain is usually 
straightforward, and in some cases, the relationship with the 
cognitive syndrome is clear; this includes (1) hereditary forms 
of VCI, particularly when manifesting at an early age, and 
(ii) cases of poststroke dementia (PSD), when the patient was 
cognitively normal before the stroke. In many other cases, this 
relationship remains uncertain, that is, in patients without any 
clinical history of stroke or in patients who develop progres-
sive cognitive decline months or years after stroke. Aspects 
that argue for a relationship include extensive (multiple or 
large) vascular lesions (infarcts, hemorrhages, white matter 
lesions [WML]), lesions in strategic brain regions, signs of 
cerebral amyloid angiopathy (CAA) on neuroimaging, and 
specific clinical features, such as a stepwise decline of cog-
nitive functions or prominent deficits of executive functions 
and processing speed.26 However, these aspects have not been 
operationalized in current diagnostic criteria.3




CAA cerebral amyloid angiopathy
CMI cerebral microinfarcts
cSS cortical superficial siderosis
ePVS enlarged perivascular space
ICH intracerebral hemorrhages
MBs microbleeds
MCI mild cognitive impairment
MRI magnetic resonance imaging
PSD poststroke dementia
SBI silent brain infarcts
SVD small-vessel disease
TCI transient cognitive impairment
VaD vascular dementia
VCI vascular cognitive impairment
WMH white matter hyperintensities
WML white matter lesions
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Reversibility
Occasionally, patients with VCI may return to normal cog-
nition particularly when cognitive deficits occurred in the 
context of an acute stroke,32 depression,33–35 heart failure,36 or 
autoimmune disorders.37 VCI is reversible in ≤20% of patients 
after stroke, with the highest rate of recovery seen shortly after 
stroke.32 Transient cognitive impairment (TCI) not necessarily 
returning to normal cognitive function is even more frequent 
and associated with a 5-fold increased risk of developing se-
vere dementia in the next 5 years.38,39 However, TCI should 
not be equated with delirium, one of the causes underlying 
TCI found in ≤25% of hospitalized stroke patients.40,41 Both 
delirium and TCI are associated with worse outcomes.38,42 
Reversal of cognitive impairment is further seen in patients 
successfully treated for depression.33,43
Mechanisms
In principle, any of the multiple etiologies of stroke (small-
vessel disease [SVD], large-artery atherosclerosis, cardioem-
bolism, or other less common etiologies of stroke) can cause 
VCI.44 However, neuroimaging and pathological studies have 
identified typical settings of vascular causes and brain paren-
chymal lesions that are associated with cognitive impairment 
(Figure 1). This has provided a framework of mechanistically 
defined VCI categories.
Multiple Infarcts (Multi-Infarct Dementia)
The presence of multiple small or large infarcts has for long 
been recognized as a cause of dementia.19 Larger infarct vol-
umes and a higher number of territorial or small subcortical 
infarcts are associated with worse cognitive performances and 
higher risks of dementia.19,45–47 There is no clear threshold for 
an overall volume of brain lesion required for the occurrence 
of VCI or VaD. This relates to several factors: first, some brain 
regions are more eloquent with regard to cognitive functions 
than others. Second, many patients have comorbid conditions, 
such as AD.48 Third, there are interindividual variations in the 
ability to compensate for both vascular and neurodegenerative 
pathologies.49–51 Nevertheless, multi-infarct dementia remains 
a valid concept.
Strategic Infarcts (Strategic Infarct Dementia)
A single small infarct may cause severe cognitive deficits 
when located in a strategic brain region. Classical anatomic 
locations for strategic infarcts include the thalamus, angular 
gyrus, and basal ganglia, including the caudate nucleus and 
globus pallidus.52–57 Voxel-based magnetic resonance imaging 
(MRI) studies have highlighted a key role of specific white 
matter tracts, in particular the anterior thalamic radiation and 
forceps minor in VCI.58–60 This finding matches earlier reports 
on patients who developed dementia in the context of small in-
farcts in the internal capsule54,61 and anterior part of the corpus 
callosum.53,62 The available data are still insufficient to draw a 
complete picture of strategic brain regions and networks rele-
vant to VCI. However, it is now recognized that most strategic 
locations integrate into larger networks or cortico-subcortical 
loops with a presumed role in cognition. It has further become 
clear that the same structures are also vulnerable to WML58–60 
and intracranial hemorrhages.53
WML and Lacunes (Subcortical Ischemic VaD)
By far, the most common cause of VCI is cerebral SVD, which 
typically manifests with WML and lacunes. MRI shows hy-
perintense signals on T2-weighted and fluid-attenuated inver-
sion recovery images termed white matter hyperintensities 
(WMH) and small cystic cavities with a signal behavior iden-
tical to cerebrospinal fluid (lacunes; Figure 2). In the general 
population, prevalence rates for WMH rise from 50% to 95% 
around 45 and 80 years of age, respectively.63,64 Small brain 
infarcts are also common65 and like WMH have been shown 
to be associated with cognitive deficits and dementia.65–67 A 
correlation between the burden of subcortical ischemic le-
sions and lower cognitive performances has been documented 
both in population-based cohorts68,69 and in hospital-based 
samples,67,70 including patients with pure SVD,71 with some 
studies suggesting a threshold effect.68,72,73 However, such 
Table 1. Diagnostic Criteria for Vascular Cognitive Impairment (VCI)*
VCI refers to all forms of cognitive deficits of vascular origin ranging from MCI to dementia. Diagnosis must be based on cognitive testing involving a minimum of 4 
cognitive domains, including executive/attention, memory, language, and visuospatial functions.
Vascular dementia (VaD) requires a decline in cognitive function and a deficit in performance in ≥2 cognitive domains that are of sufficient severity to affect 
activities of daily living.
Vascular mild cognitive impairment (VaMCI) includes 4 subtypes: amnestic, amnestic plus other domains, nonamnestic single domain, and nonamnestic multiple 
domain; VaMCI should be based on the assumption of a decline in cognitive function. Activities of daily living may be normal or mildly impaired.
Probable: A diagnosis of probable VaD or VaMCI requires the following:
 (1) Imaging evidence of cerebrovascular disease and (a) a clear temporal relationship between a vascular event (eg, stroke) and onset of cognitive deficits or (b) 
a clear relationship between the severity and pattern of cognitive impairment and the presence of diffuse subcortical vascular pathology; 
 (2) Absence of a history of gradually progressive cognitive deficits, suggesting the presence of neurodegenerative disease.
Possible: A diagnosis of possible VaD or VaMCI requires imaging evidence of cerebrovascular disease and should be made if there is no clear relationship between 
vascular disease and cognitive impairment, if the criteria for probable VaD or VaMCI are not fulfilled, if aphasia precludes proper cognitive assessment, or if there 
is a history of active cancer or psychiatric or metabolic disorders that may affect cognitive function.
Unstable VaMCI: subjects with probable of possible VaMCI whose symptoms revert to normal
MCI indicates mild cognitive impairment.
*The key distinction between VaD and VaMCI is the degree of the functional deficit. The criteria cannot be used in subjects with delirium or an active diagnosis of 
substance abuse. Criteria were derived from Gorelick et al.3
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thresholds are difficult to define given the heterogeneity of le-
sions and impact of location.
Because of the prominent appearance of WMH and la-
cunes on MRI, their anatomic location within white and 
deep gray matter, and a characteristic profile of associated 
clinical features, investigators have coined the terms sub-
cortical ischemic vascular disease and subcortical ischemic 
VaD.20,21,74–76 However, the consequences of SVD may extend 
into the cortex, manifesting both as microscopic vascular 
lesions and cortical atrophy.77–79 Cortical changes are now 
considered a clinically relevant component of SVD.13,77,80 
Still, WML and lacunes represent the most prominent 
manifestations of SVD. Pathologically, WML represent 
variable degrees of axonal loss, demyelination, and glio-
sis. However, imaging findings should not be equated with 
specific pathological changes.81 Also, MRI captures aspects 
that are usually not in the focus of pathological assessment, 
such as edema.82
Brain Hemorrhages (Hemorrhagic Dementia)
Both macroscopic intracerebral hemorrhages (ICH)83,84 and 
microbleeds (MBs)85 have been associated with cognitive de-
cline or dementia, which may manifest before or after ICH.84,86 
The underlying vascular cause in deep ICH typically is hyper-
tensive SVD,84 whereas lobar ICH is associated with CAA.84 
These conditions will be discussed later.
Global Hypoperfusion (Hypoperfusion Dementia)
Global reductions in cerebral perfusion can result in tran-
sient or permanent ischemia and, hence, cognitive deficits. 
Figure 1.  Major mechanisms underlying vascular cognitive impairment (VCI). A, Vascular causes. B, Brain parenchymal lesions 
associated with VCI. For explanations, see text. WML indicates white matter lesion (graphical realization: Antonia Weingart, Institute for 
Stroke and Dementia Research).
Figure 2.  Magnetic resonance (MR) imaging changes 
associated with vascular cognitive impairment (VCI). A, Fluid-
attenuated inversion recovery (FLAIR) image of a 64-year-old 
male patient with vascular dementia (VaD) showing extensive 
white matter hyperintensities (white arrows) and a lacune in the 
right frontal white matter (white arrowhead). B, T2*-weighted 
gradient echo scan of a 52-year-old female patient with VCI, 
demonstrating 2 microbleeds in the left occipital cortex (black 
arrowhead) as well as superficial siderosis in the frontal cortex 
predominantly on the right side (black arrowhead); inset: 
FLAIR image of the left frontal cortex displaying an enlarged 
perivascular space. In both cases, there is some indication of 
brain atrophy as reflected by a widening of sulci.
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Carotid-artery occlusion or high-grade stenosis may cause 
cognitive impairment even in the absence of macroscopic brain 
lesions.87–89 In the RECON trial (Randomized Evaluation of 
Carotid Occlusion and Neurocognition), hemodynamic failure 
(as defined by an increased oxygen extraction fraction mea-
sured by positron emission tomography imaging) on the side 
of carotid-artery occlusion was independently associated with 
cognitive impairment.90 Studies on patients with unilateral as-
ymptomatic severe carotid-artery stenosis have demonstrated 
decrements in structural brain connectivity ipsilateral to the 
stenosis88 and an increased risk of cognitive decline.89 Other 
causes of cognitive impairment induced by global reductions 
in cerebral perfusion include cardiac arrest, severe cardiac fail-
ure, arrhythmias, and severe hypotension.91–94 Pathologically, 
global hypoperfusion has been associated with border zone in-
farcts, cortical laminar necrosis, and hippocampal sclerosis.95
Mixed Vascular and AD (Mixed Dementia)
Many patients with MCI or dementia have mixed patholo-
gies.48,49,96,97 This relates to the high prevalence of both vascular and 
AD pathology in the elderly and to shared risk factors.11,98,99 In the 
Religious Orders Study and the Rush Memory and Aging Project, 
mixed vascular and AD-type pathology was the predominant find-
ing in patients diagnosed with dementia.48 Individuals with mul-
tiple pathologies were 3× more likely to be demented than were 
those with 1 pathology. In most cases, it is difficult to estimate 
their relative contribution to cognitive decline. However, vascu-
lar brain lesions lower the threshold of AD pathology required to 
induce dementia.56,100–102 Conversely, AD pathology increases the 
risk of dementia after stroke103 and contributes to cognitive decline 
in patients with VCI.104 Earlier studies have suggested a multipli-
cative effect between vascular and AD-type pathology on cogni-
tive decline,56 whereas recent studies indicate that the effects are 
additive.49,100,105 Yet, the relationship may be more complex. Novel 
autopsy data show that both large- and small-artery disease are as-
sociated with AD dementia independent from infarcts.106
Specific Arteriopathies
Several well-defined arteriopathies, such as hereditary and spo-
radic forms of CAA107–109 or hereditary forms of ischemic SVD,110 
typically manifest with cognitive decline or dementia. The most 
frequent monogenic cause of VCI is cerebral autosomal domi-
nant arteriopathy with subcortical infarcts and leukoencephalop-
athy, a severe SVD caused by NOTCH3 mutations.111–113 Cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy represents a pure form of VCI. As such, 
this condition has greatly contributed to the understanding of VCI 
mechanisms. Another, less common arteriopathy associated with 
cognitive decline and dementia is cerebral autosomal recessive 
arteriopathy with subcortical infarcts and leukoencephalopathy, a 
condition caused by HTRA1 mutations.114,115
Silent Brain Lesions of Vascular Origin: Impact 
on Cognition
Silent Brain Infarcts
Silent brain infarcts (SBI), that is, infarcts without attributable 
acute neurological symptoms, are common in elderly people. 
Their prevalence increases from ≈10% to 40% in subjects aged 
65 and 90 years, respectively, and the prevalence is even higher 
in patients with vascular risk factors.65 Most SBI are lacunes at-
tributable to SVD. In the Rotterdam scan study, the presence 
of SBI at baseline doubled the risk of dementia,66 and similar 
figures were obtained in the Framingham Offspring study.116 In 
Rotterdam, the presence of SBI was further associated with worse 
performance on cognitive testing and a steeper decline in cogni-
tive function. Thalamic infarcts were associated with a decline 
in memory performance, whereas non-thalamic infarcts were 
associated with a decline in psychomotor speed.66 A strategic 
role of silent thalamic infarcts is further suggested by an autopsy 
study in 72 subjects that found silent thalamic and basal gan-
glia lacunes to be associated with clinical dementia rating scores 
obtained before death. The impact of SBI on cognition might 
be lower in younger subjects because there was no association 
in the PURE study (Prospective Urban Rural Epidemiological), 
which included subjects aged 40 to 75 years.117
Microinfarcts: Invisible Lesions
Only recently, investigators have recognized the impact of 
cerebral microinfarcts (CMI) on cognitive function and risk 
of dementia. CMI are small ischemic lesions not visible to 
the naked eye (typically <1 mm) but detected microscopically 
during pathological examination, where they may be cystic 
or incomplete47,79 (Figure 3). These lesions represent the most 
widespread form of brain infarction and are generally attribut-
ed to SVD, although other mechanisms, such as microemboli, 
cerebral hypoperfusion, or vasoconstriction, are also discussed 
as potential causes. The presence of 1 or 2 CMI in routine neu-
ropathological specimens implies the presence of hundreds of 
CMI throughout the brain.118 CMI may be located in cortical 
or subcortical regions and are particularly common in patients 
with VCI. However, they are also frequent in AD patients and 
in unselected elderly people.119,120 CMI have been shown to be 
associated with an increased risk of dementia both in hospital-
based studies and in prospective cohorts. In a hospital-based 
series of 43 autopsy cases with low or intermediate levels of 
neurofibrillary tangle pathology, CMI explained most of the 
variance in clinical dementia rating scores even when control-
ling for other vascular lesions.121 In accord with this, a recent 
meta-analysis of data from the Honolulu-Asia Aging Study,122 
Religious Orders Study,123 and other community-based studies 
found the prevalence of CMI to be nearly twice as high in peo-
ple who died with dementia.79 The profile of cognitive deficits 
associated with CMI has not been studied in detail, but in one 
study, they were found to be associated with disturbances in 
episodic memory, semantic memory, and perceptual speed.123 
Quantifying CMI in vivo remains a challenge: they are best 
detected on ultrahigh-field MRI at 7 T,124 but may occasion-
ally be seen on conventional 3T scans.125,126 MRI is much 
more sensitive in detecting acute small infarcts detected on 
diffusion-weighted imaging, and indeed, a recent study sug-
gests that such small diffusion-weighted imaging lesions are 
indicative of an annual incidence of hundreds of new CMs.127
Microbleeds and Superficial Siderosis
MBs are small, round, well-defined foci of MRI signal void 
appearing black on gradient echo T2*-weighted scans. MBs 
are detected in 10% to 15% of elderly subjects128–130 and in 
≤80% of patients with VaD.131 They are generally considered 
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a manifestation of SVD.132,133 They have been related to fo-
cal deposits of iron-positive blood breakdown products, al-
though recent data suggest that the underlying pathology and 
mechanisms may be more heterogeneous.134 A growing body 
of evidence suggests that MBs may affect cognition. A higher 
number of MBs is associated with lower cognitive scores even 
when adjusting for vascular risk factors and other markers of 
SVD.130 They are also associated with an increased risk of 
VaD.128 In patients with vascular risk factors, multiple MBs 
were associated with incident dementia.135 An association 
between presence or number of MBs and cognitive function 
was further found in patient with transient ischemic attack or 
stroke,136 in non-demented elderly patients with SVD,137 and 
in patients with symptomatic SVD.138 The mechanisms by 
which MBs affect cognition are still debated as is the impact 
of MB location on cognitive impairment or dementia.128–130,135 
However, there is some evidence that MBs disrupt structural 
connectivity and, hence, network function.139–141
Cortical superficial siderosis (cSS) represents linear de-
posits of blood-breakdown products within the subarachnoid 
space, the leptomeninges, and the superficial cortical layers.142 
cSS is intimately connected to CAA.143 The correlate on gra-
dient echo T2*-weighted scans is a characteristic dark (signal 
void) rim along the cortical surface (Figure 2). The prevalence 
of cSS in non-demented elderly subjects is around 0.5%,142,144 
whereas the frequency in patients recruited through memory 
clinics is much higher ranging from 2% to 6%.145–147 In a study 
from South Korea,147 cSS was similarly frequent in patients 
clinically diagnosed as subcortical VCI and AD-related cogni-
tive impairment, but cSS was exclusively present in patients 
Figure 3.  Pathological findings associated with vascular cognitive impairment (VCI). A, Hemisphere section of a patient with small-
vessel disease and extensive white matter rarefication (Luxol fast blue periodic acid Schiff-reaction [LFB-PAS] stain, scale bar 1 cm); the 
arrowhead marks a lacunar infarct; boxes correspond to higher magnifications in B, C, and D. B, Enlarged perivascular space (LFB-PAS 
stain, scale bar 200 μm). C, Mild white matter rarefication (pallor; LFB-PAS stain, scale bar 500 μm). D, Marked white matter rarefication 
(pallor; LFB-PAS stain, scale bar 500 μm). E, Lacunar infarct (hematoxilin and eosin stain, scale bar 500 μm). F, Microhemorrhage with 
hemosiderin-loaded macrophages (hematoxilin and eosin stain, scale bar 200 μm). G, Microinfarct (hematoxilin and eosin stain, scale 
bar 200 μm). Images were kindly provided by Thomas Arzberger and Karl Bise, Institute for Neuropathology and Prion Research, LMU, 
Munich.
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who had a positive amyloid–positron emission tomography 
imaging scan. CSS was associated with other markers of 
CAA, including a strictly lobar location of MBs and the pres-
ence of an apolipoprotein E ɛ2 allele. cSS has further been 
reported to be associated with the apolipoprotein ɛ4 allele, 
which is also consistent with the known association between 
cSS and CAA. Whether cSS contributes to cognitive decline 
has to date not been studied in detail.
Subtle Loss of Microstructural Integrity
Among the earliest manifestations of SVD is a subtle loss 
of microstructural tissue integrity. These early stages are not 
detected by conventional MRI but are captured by diffusion 
tensor imaging.81 Measures of this technique can be quanti-
fied across the entire brain or within selected brain regions 
and are among the markers that correlate best with cognitive 
function and cognitive decline in regression models, account-
ing for age, WMH, lacunes, and other disease markers.148–150 
Moreover, the same measures enable identifying individu-
als at risk for developing cognitive decline even when mea-
sured within tissue appearing normal on conventional MRI.151 
This may allow for a completely new treatment perspective 
because current approaches usually fail when treatment is 
started in patients with advanced pathology. A valuable ad-
dition in this context has been the introduction of novel tools 
to quantify microstructural tissue damage across major white 
matter tracts in an automized way.152
Enlarged Perivascular Spaces: Disentangling 
the Influence of Different Pathologies on 
Cognitive Function
Enlarged perivascular spaces (ePVS) are a frequent MRI find-
ing in elderly people, especially in subjects with vascular 
risk factors and in patients attending memory clinics81,153,154 
(Figures 1 and 2). ePVS are associated with cognitive function 
and dementia.155–157 Typical locations include the centrum se-
miovale, basal ganglia, hippocampus, and mesencephalon.153 
ePVS are associated with markers of SVD, including WMH, 
lacunes, and retinal microvascular calibers.154,157–160 However, 
they are not specific for SVD but also associated with other 
conditions, including AD and multiple sclerosis.153 Proposed 
mechanisms for enlargement include brain atrophy, hyperten-
sion, inflammation, and changes in perivascular flow.153,161
Disentangling the influence of different lesions and im-
aging markers such as ePVS on cognitive function remains 
difficult because most markers are associated with other mark-
ers through shared disease processes (eg, SVD). Also, some 
markers, such as ePVS, may originate from multiple disease 
processes that may run in parallel. There are additional factors 
that influence the consequences of lesions on cognitive func-
tion, such as lesion location, the presence of subtle, unrec-
ognized pathology, and cognitive reserve (Figure 4). Finally, 
some pathologies such as atrophy may in part originate from 
other pathologies (see next paragraph).
Secondary Neurodegeneration: The Role of 
Brain Atrophy
Aside from causing local tissue damage, ischemic infarcts can 
induce neurodegenerative changes in remote brain regions.12,13,162 
Secondary neurodegeneration after subcortical ischemic infarcts 
is mediated by a degeneration of neuronal fiber tracts connecting 
the initial vascular injury with distant gray matter and resulting 
in focal or widespread loss of white matter and cortical thin-
ning13 (Figure 1). The mechanisms underlying secondary gray 
matter loss are poorly understood but possibly involve trans-
synaptic effects57,163 and inflammatory reactions.164 Another po-
tential mechanism is retrograde degeneration of cortical neurons 
projecting to subcortical structures as suggested by the selec-
tive loss of pyramidal cell volumes in layers III and V of the 
dorsolateral prefrontal cortex in patients with PSD.165 Changes 
of cortical morphology on MRI include a reduction of cortical 
thickness,13,166 as well as alterations in sulcal morphology.77,80 
Interestingly, the spatial patterns of cortical thinning and cogni-
tive trajectories associated with amyloid-β (Aβ) deposition dif-
fer from those associated with lacunes.167
Brain atrophy is among the strongest predictors of cogni-
tive impairment in patients with pure vascular disease,80,168 and a 
growing body of evidence suggests that the effects of subcortical 
ischemic lesions on cognitive functioning are mediated by the 
ensuing loss of cortical gray matter.169–171 In the Austrian Stroke 
Prevention Study, associations between changes in WMH load 
and cognitive functioning were no longer significant when add-
ing change in brain volume to the models.172 Together, these 
observations identify secondary neurodegeneration as a target 
for future therapeutic interventions.173
Structural and Functional Connectivity: 
Network Dysfunction Takes Center Stage
Cognitive functions emerge from communication between 
cortical and subcortical brain regions.174,175 Vascular lesions 
may disrupt network structure and function by injuring white 
matter, cortical gray matter (hubs), or subcortical gray mat-
ter. Indeed, recent work suggests that the effects of vascular 
Figure 4.  Key determinants of vascular cognitive impairment. 
For explanations, see text. AD indicates Alzheimer’s disease; and 
WML, white matter lesion.
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lesions on cognitive function are mediated through alterations 
in structural and functional connectivity (Figure 4).
Structural connectivity is assessed by diffusion imaging, 
whereas there are several ways to measure functional con-
nectivity, including resting state functional MRI and elec-
troencephalography. Several MRI studies have looked at the 
relationship between vascular lesions, structural connectivity, 
and cognitive function, with most work done in patients with 
cerebral SVD. These studies consistently found an association 
between the burden of SVD-related brain lesions and reduced 
network efficiency.140,170,176 Even more important, network 
efficiency was found to mediate the effects of SVD-related 
MRI lesions on cognitive function, and similar results were re-
ported for patients with CAA.141 Some studies have looked at 
regional connectivity, regional cortical thickness, and execu-
tive function. In accord with earlier observations,169,171 a recent 
study found reductions in frontal network efficiency to medi-
ate the effects of SVD-related lesions on frontal gray matter 
loss, as well as on executive dysfunction.170 The clinical rel-
evance of these observations is highlighted by the observation 
that lower network efficiency predicts conversion to dementia 
along with higher age and lower hippocampal volume.177
Functional connectivity has been less well explored. 
However, there is some evidence that the effects of vascular 
lesions on MCI are in part mediated by altering functional 
connectivity,178–180 and this has specifically been shown for 
frontal brain regions.181 These findings add to the growing no-
tion that disturbances in large-scale networks take center stage 
in determining cognitive decline.182,183
Poststroke Dementia
Stroke doubles the risk of dementia, with risk being high-
est immediately after stroke and remaining high thereaf-
ter.103,184–186 In a large population-based study, incident stroke 
was associated with an acute decline in cognitive function and 
both an accelerated and persistent decline of cognitive func-
tion within the following years.187
PSD refers to all types of dementia after stroke, irrespec-
tive of its cause and onset, that is, prior to, parallel with, or 
after stroke.103,185,186 Prevalence estimates for prestroke demen-
tia range from 9.1% in population-based studies to 14.4% in 
hospital-based studies.103 Estimates for the prevalence of PSD 
largely vary depending on the setting (eg, population-based 
versus hospital-based), interval from stroke, and whether pa-
tients with recurrent stroke, prestroke dementia, and aphasia 
are included.103 In previous hospital-based studies, the pooled 
prevalence of PSD ≤1 year after stroke was 20%, when ex-
cluding patients with prestroke dementia. However, these 
patients were mostly recruited in the 90s, and more recent 
studies have reported lower prevalence rates possibly because 
of therapeutic improvements and changes in case mix.188,189 
The long-term incidence of dementia starting from 3 months 
after stroke has been estimated to be 3% to 6% per year,103,190 
with slightly lower rates reported for patients with transient 
ischemic attack and minor stroke.191
Milder deficits of cognitive function in at least 1 cogni-
tive domain (poststroke MCI) are much more common after 
stroke.188,192,193 A study from Helsinki found 83% of stroke 
survivors to show impairment in at least 1 cognitive domain, 
with 50% of patients showing deficits in multiple (≥3) do-
mains when tested 3 months after stroke.192 Cognitive defi-
cits in the first days after an acute stroke may be transient32,194 
and, in some cases, reflect delirium.40,41 TCI delirium, and 
poststroke cognitive impairment all are associated with poor 
outcome, including institutionalization and mortality.38,42,195,196
Risk factors for PSD include increasing age, female sex, 
prestroke cognitive decline, poststroke cognitive impairment, 
recurrent stroke, multiple vascular risk factors (in particular, 
atrial fibrillation, smoking, and diabetes mellitus), depression, 
early seizures, and low educational status.103,185,189–191,197,198 The 
presence of at least 4 vascular risk factors increases the risk of 
dementia or death by 4-fold in elderly stroke survivors,190 but 
the influence of vascular risk factors is probably lower than 
that of stroke recurrences.199 Imaging predictors of PSD in-
clude WMH, SBI, and medial temporal lobe atrophy.103,189,198 
Interestingly, some of these factors show an even stronger as-
sociation with prestroke dementia. This particularly applies to 
temporal lobe atrophy, which is also associated with AD. Still, 
several observations suggest that the cognitive deficits in PSD 
and poststroke MCI primarily relate to vascular pathology 
rather than comorbid age-related pathologies. In an autopsy 
study on stroke patients prospectively followed until death, 
≥75% of demented subjects met current pathological criteria 
for VaD.190 Also, in the to date largest study on amyloid posi-
tron emission tomography imaging and PSD, the frequency 
of amyloid positivity in patients who developed incident PSD 
was 30%, which is similar to the point estimate for healthy 
subjects from the same age group.198,200 Of note, however, in-
dividuals with amyloid positivity exhibited a more rapid de-
cline of cognitive scores in multiple domains compared with 
amyloid-negative patients when followed over 3 years.201
There are few data on the cognitive profile of PSD and 
poststroke MCI. Among the early and most pronounced ab-
normalities are deficits in attention and executive function 
as would be expected in patients with predominant vascular 
pathology. However, deficits in other domains such as orienta-
tion, memory, and language are also common, particularly in 
those with more severe cognitive impairment.30 In light of a 
decline in mortality rates, long-term consequences of stroke 
are receiving more and more attention. As a consequence, re-
cent secondary stroke prevention trials included cognitive end 
points to their study protocols.202,203
Intracerebral Hemorrhage
Because of a lower incidence and higher case-fatality rates of 
ICH compared with ischemic stroke, there are less data on the 
relationship between ICH and cognitive decline. A substantial 
proportion of patients admitted for ICH have preexisting cogni-
tive impairment or dementia. Of 417 patients with ICH who 
were systematically assessed for preadmission cognitive status 
by the Information Questionnaire on Cognitive Decline in the 
Elderly, 14% had cognitive impairment no dementia, and 16% 
had dementia.86 Among those with lobar ICH, the prevalence of 
preexisting dementia was 23%. Factors associated with preex-
isting dementia in lobar ICH were higher age, lower educational 
level, and cortical atrophy. Factors associated with preexisting 
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dementia in deep ICH were old territorial vascular lesions and 
a higher burden of white matter changes. The majority of pa-
tients with preexisting dementia who came to autopsy had lobar 
ICH. All of them had AD-type and CAA pathology, whereas the 
single patient with deep ICH had SVD without AD-type pathol-
ogy.86 Hence, preexisting dementia is frequent in patients with 
ICH and may be the consequence of 2 distinct mechanisms: 
neurodegeneration with AD-type pathology and CAA in lobar 
ICH versus vascular processes in deep ICH.
The risk of cognitive decline after ICH remains high even 
years after the ICH.83,84,204,205 In a cross-sectional study on 78 
ICH survivors studied at a mean of 40 months after the event, 
23% had developed new-onset dementia. Cognitive impair-
ment without dementia was observed in 77% of patients un-
dergoing detailed testing.204 Cognitive deficits predominantly 
involved episodic memory, psychomotor speed, and executive 
function.204
Longitudinal data with long-term follow-up are available 
from the Lille ICH cohort.83,84 Among 167 consecutive ICH 
survivors without preexisting dementia, 37% were found to 
decline over a median interval of 4 years.83 Factors associated 
with cognitive decline were previous stroke or TIA, preexist-
ing cognitive impairment, and cortical atrophy.83 This suggests 
that the causes and mechanism underlying cognitive decline 
after ICH are mostly already present at the time of ICH.83 In 
a more recent study on 218 ICH survivors free of dementia 
6 months after the acute event and followed for a median in-
terval of 6 years, 29% developed dementia.84 The incidence 
rate of dementia was much higher in those with lobar ICH 
compared with those with deep ICH. Predictors of new-onset 
dementia were disseminated cSS, cortical atrophy, a higher 
number of MBs, and higher age, suggesting an important role 
of CAA. Collectively, these findings suggest that in many ICH 
patients, dementia is the consequence of a chronic disease 
process and that avoiding the ICH may not be enough to pre-
vent dementia.84
Cerebral Amyloid Angiopathies
CAA refers to a heterogeneous group of biochemically and 
genetically distinct conditions that are characterized by am-
yloid deposition in the walls of leptomeningeal and cortical 
arteries, arterioles, and less frequently capillaries and veins. 
By far, the most common form is sporadic CAA with vascular 
deposition of Aβ.
Sporadic Aβ-Related CAA
Aβ-related sporadic CAA is found in normal elderly subjects, 
in patients with AD, and in Down’s syndrome.206 Estimates 
for moderate to severe CAA range from ≈2% in those aged 
65 to 74 years to >20% in those aged >85 years.207–209 In pa-
tients with concomitant AD, the prevalence of CAA at autopsy 
is >80%.209,210 In the population-based Honolulu-Asia Aging 
Study, 44.1% of patients had autopsy-proven CAA in at least 
1 neocortical area. CAA was associated with more neurofi-
brillary tangles, more neuritic plaques, and greater probability 
to have at least 1 apolipoprotein E ε4 allele,211 reflecting the 
known overlap with AD.
Aβ-CAA typically manifests with lobar ICH, cognitive 
impairment, or both.108,212 Advanced CAA has been shown 
to be associated with worse cognitive performance indepen-
dent of AD pathology in several autopsy studies.211 In the 
largest study to date, CAA was associated with an increased 
rate of decline in global cognition, perceptual speed, episodic 
memory, and semantic memory.213 The mechanism by which 
CAA causes cognitive decline are insufficiently understood 
but likely include ischemic injury to the white matter,214 mi-
cro- and macrobleeds, and microinfarcts and an ensuing loss 
of functional and structural network integrity.141
Aβ-CAA is usually diagnosed on the basis of clinical and 
radiological findings. Radiological findings supporting the di-
agnosis of CAA include multiple lobar hemorrhages,215 mul-
tiple MBs, particularly in the temporal and occipital lobes,216 
and cSS.142,143 The diagnostic utility of amyloid positron emis-
sion tomography imaging217,218 and measurements of Aβ levels 
in cerebrospinal fluid219 seems to be rather limited. This in part 
relates to limited specificity in distinguishing between CAA 
and AD.
Hereditary Forms
There are several hereditary forms of CAA, which are char-
acterized by specific mutations and an accumulation of spe-
cific proteins in cerebral blood vessels (reviewed in Biffi and 
Greenberg209). Clinical presentations differ between condi-
tions but most of them cause dementia. Among the most thor-
oughly studied conditions is hereditary cerebral hemorrhage 
with amyloidosis, Dutch type, which is caused by a point 
mutation in the amyloid precursor protein gene.220 Dementia 
is common and has been shown to develop independent of 
plaques and neurofibrillary tangles.107 Hence, this condition 
provides further proof that CAA alone is sufficient to cause 
dementia.
Diagnostic Evaluation
Overview on Cognitive Domains to be Assessed 
in VCI
Typical reasons for patient referral include complaint by the 
patient, a related party, or health professionals. Although 
extensive neuropsychological assessment by a trained inves-
tigator may be optimal, a shorter bedside evaluation with a 
screening instrument is often more appropriate. Screening 
tests should cover the following cognitive domains24: (1) at-
tention and processing speed; (2) frontal–executive function; 
(3) learning and memory; (4) language; (5) visuo–construc-
tional–perceptual ability; (6) praxis–gnosis–body schema; 
and (7) social cognition.
Executive function includes various processes necessary 
for an effective and appropriate behavior, such as initiation, 
planning, hypothesis generation, cognitive flexibility, deci-
sion making, regulation, judgment, feedback utilization, and 
self-perception.221 Various aspects of executive functions are 
assessed in the Montreal Cognitive Assessment battery using 
tasks adapted from the Trail Making B task, a phonemic flu-
ency task, and a 2-item verbal abstraction task. Verbal mem-
ory includes both immediate recall (a measure of attention) 
and delayed recall. Although delayed recall of logical content 
is most closely linked to amnestic MCI and AD, delayed re-
call of word lists and visual content is most closely linked 
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to vascular brain injury.222 Care should be taken to standard-
ization and the availability of normative data when choosing 
specific test batteries.
Screening Instruments
The Mini-Mental State Examination223 is the most widely used 
screening test. However, it was designed for AD and has a strong 
emphasis on language and memory and not on executive dys-
function, a hallmark of VCI. The Montreal Cognitive Assessment 
includes an evaluation of executive functions and has, thus, been 
recommended for use in VCI either in full length224 or (less op-
timal) in an abbreviated version. It is sensitive to the cognitive 
profile of stroke patients, easy to administer, and available in 
multiple languages.224,225 The Telephone Interview for Cognitive 
Status has been validated both in the general population and in 
patients with stroke with good sensitivity and specificity and 
with better performance in detecting multiple-domain versus 
single-domain MCI.226,227 However, telephone interviews are 
limited by inability to test visuo–executive items.
Neuropsychological Assessment
The National Institute of Neurological disorders and Stroke—
Canadian Stroke Network Vascular Cognitive Impairment 
Harmonized battery was developed by a consensus process 
among experts and is undergoing validation in several lan-
guages.28 This battery aims at maximizing information ob-
tained from relatively few tests with well-validated tasks. It 
is organized such that multiple measures can be derived from 
a single and simple test, where one brief test provides insight 
into different domains. The battery consists of 3 sets of tests 
that can be applied in 60, 30, or 5 minutes.28 However, there 
are alternative test batteries. Key issues include the need to 
administer a broad range of cognitive tests that capture dif-
ferent aspects of cognitive function and that are normed for 
language/ethnicity, age, education, and setting.
Given the high frequency of preexisting dementia or cog-
nitive deficits in patients with stroke, there is broad interest 
in determining premorbid cognitive status. The most widely 
used scales for this purpose are the Informant Questionnaire 
for Cognitive Decline in the Elderly228 and the AD8 Screening 
Interview,229 which should be completed by a related party. 
Cognitive symptoms must be separated from depression.34 
And again, the choice of assessment tools should depend 
on the setting and severity of cognitive impairment. Widely 
used tests for depression include the Hamilton Depression 
Rating Scale230 and the Center for Epidemiological Studies 
Depression Scale.231 The Geriatric Depression Scale232 is also 
widely used but contains questions about cognition, which 
must be considered when interpreting the results. The Cornell 
Scale for Depression in Dementia233 shows poor sensitivity to 
changes over time. The Dementia Mood Assessment Scale has 
high sensitivity, but relies on the rating of the interviewer.234
Risk Factors
A detailed discussion of risk factors for VCI, which are partly 
covered in previous sections and below, is beyond the scope of 
this review. Risk factors broadly overlap with those for stroke. 
The interested reader is referred to recent topical reviews3,11 
and to references provided in Table 2.
Prevention
Preventive interventions may have a modest effect at the individ-
ual level, but lead to a major reduction in the burden of VCI at the 
population level. Interventions include lifestyle modifications, 
the control of vascular risk factors, treatment of concomitant vas-
cular disease, and established strategies for stroke prevention.3
Lifestyle Factors
A lower education level is associated with an increased risk 
of dementia of any cause (vascular, degenerative, or mixed). 
However, there is no evidence for a protective influence of 
education, cognitive training, and any other structured cogni-
tive intervention on the occurrence of vascular or degenerative 
brain lesions. Available data suggest that education attenuates 
the impact of brain pathology on clinical expression rather 
than influencing the occurrence or progression of brain pa-
thology.11,50 Whether smoking cessation reduces the risk of 
cognitive decline remains uncertain. However, former smok-
ers show a reduced risk of cognitive decline when compared 
with current smokers.11,237
The most convincing evidence for an influence of diet on 
VCI risk comes from studies on vitamin E, acting as an anti-
oxidant, fish, n-3 fatty acids, polyunsaturated fats, B12 vita-
min, and folates, that is, components found in Mediterranean 
diet.249 Several prospective observational studies have shown 
that adherence to such a diet is associated with a lower risk 
of AD and cognitive decline. However, there are few specific 
data for VCI.11
Physical activity has beneficial effects on synaptogenesis, 
neurogenesis, and vascular health and might, therefore, reduce 
the risk of cognitive impairment. Indeed, observational stud-
ies suggest a beneficial influence on risk of cognitive decline, 
VaD, AD, and dementia in general.11 A beneficial effect of 
physical activity on cognitive function is further suggested by 
randomized trials in patients at risk for AD250 and by multi-
component interventions that included physical activity.239
Overweight and obesity are important risk factors for 
cognitive decline and dementia in general. However, disen-
tangling the specific influence of obesity from the influence 
of insulin resistance and other components of the metabolic 
syndrome on cognitive decline is difficult. Also, there is no 
interventional study that examined the effect of weight reduc-
tion on the risk of cognitive decline.11
Vascular Risk Factors and Concomitant Vascular 
Disease
The efficacy of blood pressure (BP) lowering to prevent cog-
nitive impairment in the elderly beyond stroke prevention is 
still controversial.3 This in part relates to methodological limi-
tations shared by BP-lowering trials.11 However, in light of 
the documented benefit of BP-lowering therapy on vascular 
outcomes, it is recommended to treat hypertension in people 
at risk for VCI.3
The level of evidence that treating diabetes mellitus and 
hyperglycemia reduces the risk of VCI and dementia in gen-
eral is likewise low,11,251,252 but the benefit on multiple target 
organs (heart, eye, and kidney) is important enough to rec-
ommend strict glycemic control. Also, glycemic control has 
been shown to restore deficits in cerebral perfusion in diabetic 
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patients.245 From the 2 statin trials that evaluated cognition as a 
secondary end point, there is no evidence that statin treatment 
reduces the risk of cognitive decline or incident dementia. 
However, these studies were not powered to answer the ques-
tion, and follow-up may have been too short.253,254
Based on observational data, prevention of concomitant 
vascular disease in particular coronary artery disease, chronic 
heart failure, or chronic kidney disease is a reasonable strat-
egy to prevent VCI.3 Yet, there are few data from randomized 
controlled trials to support this.
Cerebrovascular Disease
Few trials on primary or secondary stroke prevention provided 
cognitive end points. The SPS3 trial (Secondary Prevention 
of Small Subcortical Strokes) had a 2-by-2 factorial design 
and compared the effect of dual antiplatelet treatment versus 
single aspirin and intensive BP lowering versus usual targets 
in patients with small subcortical infarcts. There was no sig-
nificant treatment effect on cognitive end points with either 
dual antiplatelet therapy or intensive BP lowering.203 The 
PRoFESS trial (Prevention Regimen for Effectively Avoiding 
Second Strokes), which included patients with ischemic 
stroke, found no benefit of 25 mg of aspirin plus 200 mg of 
extended-release dipyridamole twice daily for risk of cogni-
tive decline or dementia compared with 75 mg of clopidogrel 
once a day.202 However, follow-up in these trials may have 
been too short for an effect on cognition. In the PROGRESS 
trial (Perindopril Protection Against Recurrent Stroke Study), 
treatment with 4 mg of perindopril daily showed a reduction 
in the risk of dementia in the subgroup of patients with a prior 
history of stroke when compared with placebo.255 Active treat-
ment further stopped or delayed the progression of WMH.256
Whether patients with SBI or extensive WMH but without 
a history of stroke benefit from antiplatelet or BP-lowering 
therapy is currently unknown, and current guidelines and 
expert statements provide no recommendations on how to 
treat these patients.3
Multicomponent Interventions
Multicomponent interventions take a comprehensive approach 
by targeting multiple risk factors and domains in parallel. 
The ASPIS trial (Austrian Polyintervention Study to Prevent 
Cognitive Decline After Ischemic Stroke)257 found no benefit 
of a multicomponent intervention that focused on lifestyle and 
vascular risk factors, compared with standard care in patients 
with stroke. However, sample size was small and follow-up was 
only 2 years. The FINGER trial (Finnish Geriatric Intervention 
Study to Prevent Cognitive Impairment and Disability)239 re-
cruited 1260 at-risk individuals aged 60 to 77 years, randomly 
assigned to either a 2-year course of multidomain intervention 
(nutritional advice, exercise, cognitive training, and vascular 
risk monitoring) or general health advice. Subjects randomized 
to the multidomain intervention had better cognitive outcomes 
than controls. Additional trials are currently ongoing.
Treatment
General management principles for VCI are those of MCI and 
dementia and include the treatment of comorbidities, including 
psychological and behavioral symptoms, providing informa-
tion and support to the patient and caregivers and maximizing 
independence.3,18 The observed modest effect of symptomatic 
treatment in patients with AD together with preclinical results 
and pathological evidence for a cholinergic deficit in VCI258 
has prompted randomized controlled trials with choline ester-
ase inhibitors and memantine in patients with VaD. Two trials 
with galantamine showed no significant treatment benefit for 
clinician’s global impression of change, activities of daily liv-
ing, and neuropsychiatric symptoms.259,260 However, there was 
a significant benefit for cognition in one of the trials.260 Among 
the 3 trials conducted with donepezil, all found a significant 
Table 2. Risk Factors for VCI
Risk Factors Strength of Evidence* References
Nonmodifiable
 Age Strong Pendlebury and Rothwell103, Leys et al185, Allan et al190, 
Narasimhalu et al191, Yang et al198, Kalaria et al235
 Female sex Some evidence for PSD Pendlebury and Rothwell103
 Genetic factors Weak (few specific risk genes known) Haffner et al110, Schrijvers et al236
Modifiable
 Education Some evidence Dichgans and Zietemann11, Zieren et al50, Kalaria et al235
 Smoking Some evidence Dichgans and Zietemann11, Anstey et al237, Rusanen et al238
 Physical activity Some evidence Ngandu et al239, Aarsland et al240
 Obesity and body mass index Some evidence Gorelick et al3, Dichgans and Zietemann11, Anstey et al241
 Hypertension Strong for hypertension in midlife Dichgans and Zietemann11, Skoog et al242, Kivipelto et al243, 
Iadecola et al244
 Chronic hyperglycemia, diabetes mellitus Strong Gorelick et al3, Dichgans and Zietemann11, Yang et al198, 
Cosentino et al245, Panza et al246, Zietemann et al247
 Lipids, dyslipidemia Some evidence for total cholesterol levels in midlife Gorelick et al3, Dichgans and Zietemann11, Solomon et al248
PSD indicates poststroke dementia; VaD, vascular dementia; and VCI, vascular cognitive impairment.
*In some cases, the relationship has been established for VaD but not for VCI in general.
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benefit for cognition,261–263 while only 1 showed a significant 
global benefit,262 and only 1 showed a benefit for activities of 
daily living.261 Donepezil was further tested in 168 patients 
with cerebral autosomal dominant arteriopathy with subcor-
tical infarcts and leukoencephalopathy, who had cognitive 
impairment, and found to have no effect on the primary cogni-
tive end point. However, improvements were noted on several 
measures of executive function.264 In the single trial of rivastig-
mine, there was a significant benefit on the cognition without 
significant global benefit or benefit on activities of daily liv-
ing.265 And the same was seen in 2 studies with the N-methyl 
d-aspartate antagonist memantine. Despite the small effect on 
cognition, some experts recommend considering donepezil for 
cognitive enhancement in patients with VaD.3
Conclusion
Recent work has led to a substantially improved understand-
ing on how vascular brain injury affects cognition. However, 
more work is required to disentangle the effects of vascular 
factors and neurodegenerative disease. Preventing vascular 
injury remains a promising approach to reduce the global bur-
den of dementia, but additional efforts are needed to define the 
optimal strategy for prevention and develop efficient symp-
tomatic treatments.
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